10:02 AM EST, 11/17/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that Canadian regulator Health Canada has approved its six-month 45mg dose of Lupron Depot to treat advanced prostate cancer.
The company said the new approval of Lupron Depot adds to its 7.5 mg, (1-Month), 22.5 mg (3-Month), and 30 mg (4-Month) strength doses.
Price: 234.73, Change: +2.37, Percent Change: +1.02